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AbstrAct
Introduction There is some evidence that non-steroidal 
anti-inflammatory drugs (NSAIDs), in particular celecoxib, 
might possess not only a symptomatic efficacy but also 
disease-modifying properties in ankylosing spondylitis 
(AS), retarding the progression of structural damage in 
the spine if taken continuously. In contrast, this remains 
controversial for tumour necrosis factor alpha (TNF-α) 
inhibitors, despite their good clinical efficacy. The impact 
of a combined therapy (a TNF inhibitor plus an NSAID) on 
radiographic spinal progression in AS is unclear.
Methods and analysis The aim of this study is 
to evaluate the impact of treatment with an NSAID 
(celecoxib) when added to a TNF inhibitor (golimumab) 
compared with TNF inhibitor (golimumab) alone on 
progression of structural damage in the spine over 2 years 
in patients with AS. The study consists of a 6-week 
screening period, a 12-week period (phase I: run-in 
phase) of treatment with golimumab for all subjects 
followed by a 96-week controlled treatment period 
(phase II: core phase) with golimumab plus celecoxib 
versus golimumab alone, and a safety follow-up period 
of 4 weeks. At week 108, the primary study endpoint 
radiographic spinal progression (as assessed by the 
change in the modified Stoke Ankylosing Spondylitis Spine 
Score after 2 years) will be evaluated.
Ethics and dissemination The study will be performed 
according to the principles of good clinical practice and the 
German drug law. The written approval of the independent 
ethics committee and of the German federal authority have 
been obtained. On study completion, results are expected 
to be published in a peer-reviewed journal.
Trial registration number  ClinicalTrials. gov register 
(NCT02758782) and European Union Clinical Trials Register 
(EudraCT No 2016-000615-33).
InTroducTIon
Ankylosing spondylitis (AS) is a chronic 
inflammatory disease of unknown aetiology 
with primary involvement of the axial skeleton 
Strengths and limitations of this study
 ► This is the first prospective randomised controlled 
multicentre trial with the objective to investigate 
the effect of a combination of a tumour necrosis 
factor (TNF)  inhibitor with a non-steroidal anti-
inflammatory disease (NSAID) on radiographic 
spinal progression in ankylosing spondylitis.
 ► The primary outcome measure (radiographic spinal 
progression) will be evaluated by two independent 
readers blinded for the time-point and all clinical 
data including treatment allocation, and is therefore, 
not affected by the open-label study design.
 ► Patient population consists of patients at high risk of 
radiographic spinal progression.
 ► Study is conducted only in one country (Germany).
 ► The intervention is not masked/blinded.
 ► Highly selected patient population.
 ► Assumptions made for the sample size calculation 
are based on data obtained separately for TNF 
inhibitors and NSAIDs.
group.bmj.com on September 28, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Proft F, et al. BMJ Open 2017;7:e014591. doi:10.1136/bmjopen-2016-014591
Open Access 
(sacroiliac joint (SIJ) and spine), starting in most of the 
cases in subjects under 45 years of age (mean age onset 
about 26 years), with a strong association with the major 
histocompatibility complex class I antigen HLA-B27, 
which is positive in 80%–90% of the patients.1 Patients with 
AS can develop peripheral arthritis and enthesitis, as well 
as extra-articular manifestations such as anterior uveitis, 
psoriasis and inflammatory bowel disease.2 The preva-
lence of AS is estimated to be between 0.1% and 1.4%.3 
The disease is characterised by the presence of active 
inflammation in the SIJ and the spine, which manifests 
as pain and stiffness, and by excessive new bone forma-
tion (leading to the development of syndesmophytes and 
ankylosis in the same areas). This results in a significant 
functional impairment in up to 40% of the patients.4 5 
Given the young age at disease onset in the majority of 
patients, impairment of the functional status in AS causing 
disability has a relevant socioeconomic impact.6 Reduc-
tion of clinical burden and prevention of disability can 
probably be best achieved by early and adequate treatment 
targeting both inflammation and new bone formation. 
According to the Assessment of SpondyloArthritis inter-
national Society (ASAS) and European League Against 
Rheumatism recommendations, the first-line therapy 
for patients with AS are non-steroidal anti-inflammatory 
drugs (NSAIDs), including selective cyclo-oxygenase-2 
(COX-2) antagonists, along with education and contin-
uous exercise/physiotherapy.7 Therapy with conventional 
disease-modifying antirheumatic drugs (DMARDs) such 
as sulfasalazine or methotrexate may have some beneficial 
effect in patients with peripheral joint involvement, but in 
general is not effective for the treatment of axial involve-
ment.8–10 For those patients who have a poor response to 
NSAIDs, contraindications or intolerance for NSAIDs, the 
only effective treatment currently available is the therapy 
with tumour necrosis factor (TNF) α inhibitors7 or with 
a recently introduced monoclonal antibody against 
interleukin-17 secukinumab.11 There is some evidence 
that NSAIDs, in particular celecoxib, might possess not 
only a symptomatic efficacy but also disease-modifying 
properties in AS, retarding the progression of structural 
damage (syndesmophytes and ankylosis) in the spine if 
taken continuously.12 This might be explained by a direct 
inhibitory effect on osteoblast genesis and activity.13 This 
effect was especially evident in patients with AS with 
elevated C reactive protein (CRP),14 which is also consid-
ered a risk factor for radiographic spinal progression in 
AS.15 The data from the German Spondyloarthritis Incep-
tion Cohort (GESPIC) showed a similar protective effect 
against radiographic spinal progression in those patients 
who had high NSAIDs intake (defined as >50% of the 
maximum recommended dose) and who were at high 
risk for radiographic spinal progression (due to presence 
of syndesmophytes and/or elevated CRP) at baseline.16 
For diclofenac, a non-selective COX inhibitor, such effect 
was, however, not proven in a recently published trial.17
The data on the effect of TNF inhibitors on radiographic 
spinal progression in ankylosing spondylitis—despite 
their high anti-inflammatory efficacy—remains contro-
versial. While some studies could not show a retardation 
of radiographic spinal progression in AS over a period of 
218–20 or 421 years, there are three observational studies 
suggesting that it may take more than 4 years to detect 
such an effect22–24 and that early (within the first 5 or 10 
years of the disease) initiation of anti-TNF therapy might 
play a key role.23 24 However, no prospective controlled 
trials have been conducted so far to confirm these obser-
vations.
Many patients with AS treated with a TNF inhibitor 
discontinue their NSAIDs due to good symptom control.25 
Therefore, it has not been possible until now to answer 
the question of the impact of a combined therapy (TNF 
inhibitor and NSAID) on radiographic spinal progres-
sion. It is crucial to clarify whether adding an NSAID 
(especially a COX-2 selective one) to TNF inhibitor treat-
ment is able to stop or reduce radiographic progression, 
especially in patients at high risk (ie, with elevated CRP 
and/or with already present syndesmophytes). Recently, 
results of an observational study indicating inhibition of 
radiographic spinal progression with a combination of a 
TNF inhibitor with a high-dose NSAID were presented26 
stressing a need for a prospective interventional trial.
The aim of this prospective study is to evaluate the 
impact of treatment with an NSAID celecoxib added to 
a TNF inhibitor golimumab compared with golimumab 
alone on progression of structural damage in the spine 
over 2 years in patients with AS.
MeThods and analysIs
study design
This study is a randomised, controlled, multicentre, 
open-label clinical trial. The study consists of a 6-week 
screening period, a 12-week period (phase I: run-in 
phase) of treatment with golimumab 50 mg subcutane-
ously every 4 weeks for all subjects followed by a 96-week 
controlled treatment period (phase II: core phase) with 
golimumab plus celecoxib versus golimumab alone, and 
a safety follow-up period of 4 weeks (figure 1). Only 
subjects with a good clinical response to golimumab 
in the phase I (improvement of the Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) score 
by ≥2 absolute points on a 0–10 scale response at week 
12) will be eligible for phase II and will be randomised 
based on a 1:1 ratio to receive golimumab 50 mg subcu-
taneously every 4 weeks plus celecoxib (in a daily dose of 
400 mg/day) or golimumab 50 mg subcutaneously every 
4 weeks alone for another 96 weeks. At week 108, the 
primary study endpoint (radiographic spinal progression 
defined as the change in the modified Stoke Ankylosing 
Spondylitis Spine Score (mSASSS)27 after 2 years) will 
be evaluated. MRI of the spine and sacroiliac joints will 
be performed at baseline (week 0), and at week 108 (or 
in case of early termination at week 84 or later) in a 
substudy of approximately 60 patients with no contrain-
dication for this investigation.
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Patients
Included patients will be 18 years and older with AS 
fulfilling the modified New York Criteria28 with an active 
disease (BASDAI ≥4), history of an inadequate response 
to at least two NSAIDs and at least one of the two 
following risk factors for radiographic spinal progression: 
elevated CRP or already present syndesmophyte(s) at 
screening and give written informed consent. Key inclu-
sion and exclusion criteria are shown in table 1. Study 
participants will be recruited from 21 rheumatological 
centres throughout Germany between September 2016 
and presumably February 2018. One hundred and ninety 
patients shall be assessed for eligibility (assuming a 10% 
screening failure rate), so that 170 patients with active AS 
despite treatment with NSAIDs alone will be included in 
the phase I of the trial and treated with golimumab. Only 
patients with good clinical response (BASDAI reduction 
by ≥2 absolute points (on a 0–10 scale) after 12 weeks of 
golimumab treatment will be enrolled in the phase II 
(core phase) of the trial. Based on the efficacy results 
from a phase III study with golimumab in AS,29 we assume 
that approximately 60% (n=100) of the patients included 
in phase I will continue in to phase II of the study. Thus, 
100 patients (n=50 in each group) will enter phase II of 
the trial (intention-to-treat population (ITT) after 1:1 
randomisation and will be analysed for the primary and 
secondary outcome parameters.
outcome parameters
The study outcome parameters are summarised in 
table 2. The primary outcome parameter of the study is 
radiographic spinal progression measured by the change 
in the mSASSS after 2 years of treatment (primary 
endpoint). Secondary outcome parameters include new 
Figure 1 Design of the Comparison of the effect of treatment with Non-steroidal anti-inflammatory drugs added to antitumour 
necrosis factor (anti-TNF) therapy versus anti-TNF therapy alone on progression of StrUctural damage in the spine over 2 years 
in patients with ankyLosing spondylitis (CONSUL) study.
Table 1 Main inclusion and exclusion criteria of the CONSUL study
Inclusion criteria Exclusion criteria
  Age ≥18 years Presence of total spinal ankylosis
  Definite diagnosis of AS according to the modified New York 
criteria
History of primary non-response to previous anti-TNF therapy 
(if any)
   Active disease (defined as BASDAI≥4) Contraindications for the treatment with golimumab and/or 
celecoxib
  History of an inadequate response to a therapeutic trials of 
at least two NSAIDs
  Risk factors for radiographic spinal progression (defined as 
elevated CRP or existing syndesmophytes) at screening
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C reactive protein; NSAIDs, non-steroidal anti- 
inflammatory drugs; TNF, tumour necrosis factor.
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syndesmophyte formation or progression of existing 
syndesmophytes after 2 years of treatment, change of the 
bone and cartilage biomarkers serum levels change of 
the enteric microbiome profile, change of osteitis score 
and scores for the chronic postinflammatory changes 
in the spine and sacroiliac joints on MRI by Berlin 
MRI scoring method (in the MRI substudy only) and 
improvement of disease activity, function, axial mobility 
and quality of life. Safety outcome parameters include 
evaluation of adverse events (AEs), serious AE and AEs 
of interest: infections, malignancies, gastrointestinal 
events (ulceration, bleeding, perforation, gastric outlet 
obstruction), cardiovascular events (myocardial infarc-
tion, stroke, pulmonary artery embolism, peripheral 
arterial or venous thrombosis), renal impairment (creat-
inine >1.8 mg/dL or increase >0.5 mg/dL vs baseline) 
and substantial (more than fivefold) liver enzyme eleva-
tion.
data analysis plan
The study consists of a 12-week run-in period, 96-week 
core period (randomised treatment) and 4-week 
follow-up period. The primary efficacy endpoint will be 
the absolute progression of the mSASSS score after 2 years 
of therapy in both treatment groups. The primary analysis 
will be based on the mean of the mSASSS scores obtained 
by two trained readers for the spinal X-rays performed at 
inclusion in the study and at week 108 in the ITT popula-
tion. For the purposes of the efficacy and safety analysis, a 
database lock will occur, once all data up to week 112 has 
been collected and cleaned.
Table 2 Main outcome parameters of the CONSUL study
Efficacy Safety
Primary endpoint
 ► Radiographic spinal progression measured by the change 
in the mSASSS after 2 years of treatment.
AEs, serious AE and AE of interest until week 112
Secondary endpoints
 ►New syndesmophyte formation or progression of existing 
syndesmophytes after 2 years of treatment
 ► Improvement of disease activity, function, axial mobility 
and quality of life measures at week 12 and week 108 in 
comparison to baseline according to:
 ► BASDAI
 ► ASDAS
 ► CRP and ESR
 ► BASFI
 ► BASMI and chest expansion
 ► Global assessment (patient/physician), general pain 
and nocturnal pain on the NRS
 ► ASAS Health Index
 ► PhASS
 ► PASS
 ► Percentage of subjects who achieve an ASAS20, 
ASAS40, ASAS partial remission, BASDAI50 responses 
and ASDAS inactive disease state in comparison to 
baseline
 ►Change of the bone and cartilage biomarkers serum levels 
at week 108 in comparison to baseline and their relevance 
for the prediction of radiographic progression
 ►Change of the enteric microbiome profile at week 108 in 
comparison to baseline
 ►Change of osteitis score and scores for the chronic post-
inflammatory changes in the spine and sacroiliac joints on 
MRI by Berlin MRI scoring method at week 12 and week 
108 in comparison to baseline (MRI substudy only)
AEs, adverse events ASDAS, Ankylosing Spondylitis Disease Activity Score; ASAS, Assessment of SpondyloArthritis International Society; 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing 
Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; mSASSS, modified Stoke Ankylosing Spondylitis 
Spine Score; NRS, numeric rating scale; PASS, Patient Acceptable Symptom State; PhASS, Physician Acceptable Symptom State.
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statistical analysis
The primary analysis will be based on all patients who 
entered phase II of the trial (ITT population). Multiple 
imputation methods with mSASSS score at baseline 
as covariate will be applied to deal with missing radio-
graphs in the primary analysis. The Mann-Whitney test 
will be used to compare the primary outcome (change 
in the mSASSS score) between the treatment groups. 
Cumulative probability plots will be built to visualise 
the finding. In a secondary analysis, the Mann-Whitney 
test will be used to compare radiographic progres-
sion in the subgroup of patients with complete sets of 
radiographs. A likelihood approach will be applied to 
deal with missing data in secondary outcome parame-
ters assessed at multiple time points. For that reason, 
linear mixed models will be applied to compare means 
of secondary outcome parameters over time. A non-re-
sponder imputation for missing response data and χ2 
tests will additionally be applied to compare response 
rates. Two-sided p values <0.05 will be considered to be 
statistically significant.
sample size justification
The sample size calculation is based on the findings of 
Kroon et al,14 our own results from GESPIC Cohort16 
and those of Braun et al.21 We assume a worsening in 
the mSASSS score of 1.7±2.8 in patients of the control 
group and of 0.2±1.6 in patients with continuous NSAIDs 
intake. We considered such a difference of 1.5 mSASSS 
units as clinically relevant and planned the sample size 
of this study by means of a two-sided (α=0.05) Welch-Sat-
terthwaite t-test accordingly. To detect the mentioned 
difference with an 80% power, the sample size of n=38 
in each group is needed in the phase II of the trail. 
This is also true if the Mann-Whitney test is applied. 
However, the power will decrease by the application of 
multiple imputations to deal with missing radiographs 
of dropouts in the ITT population. Considering that 
all subjects enrolled in the phase II will be responders 
to golimumab therapy receiving this same treatment for 
the whole period of the trial, along with our experience 
in conducting randomised controlled trials, we presume 
dropout rates of less than 20% during phase II. For this 
reason and based on our own mSASSS data, we expect an 
increase in the variance of mSASSS progression because 
of multiple imputation by less than 25%. Considering 
this possible increase, a sample size of n=100 patients is 
needed for phase II of the trial to detect the expected and 
clinically relevant difference of an average 1.5 mSASSS 
points with an 80% power in the ITT population. In 
addition, we assumed that 60% of the subjects enrolled 
in phase I of the study would be eligible for randomisa-
tion and participation in phase II (based on the rate of 
the BASDAI50 response in patients with AS with elevated 
CRP), giving a total n=170 subjects to be included in the 
phase I of the trial.
ethics and dissemination
The study will be performed according to the International 
Conference of Harmonisation Good Clinical Practice 
guidelines and the German drug law (Arzneimittelge-
setz). The written approval of the central independent 
ethics committee (Ethics Committee of the Federal 
State Berlin), of the German federal authority (Paul-Eh-
rlich-Institut, Langen, Germany) and of the local ethics 
committees of the study centres have been obtained. On 
study completion, results are expected to be published in 
a peer-reviewed journal.
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